Back to Results
First PageMeta Content
Cancer treatments / Breast cancer / HER2/neu / Adjuvant therapy / Oncotype DX / MammaPrint / Medicine / Ribbon symbolism / Oncology


Predicting residual risk of recurrence after neoadjuvant chemotherapy - a retrospective analysis of EndoPredict® in the GeparTrio trial Sibylle Loibl1, Jan C Brase2, Stephan Gade1, Jens Huober3, Kristin Krappmann2, Knut
Add to Reading List

Document Date: 2014-12-11 08:05:49

Open Document

File Size: 491,05 KB

Share Result on Facebook

City

Mittendorf / Ulm / Cologne / Hannover / San Antonio / Tübingen / Molekularpathologie Neuss / Neu-Isenburg / /

Company

Minckwitz1 / Cox / 2Sividon Diagnostics / /

Country

Germany / /

Currency

pence / /

/

Facility

University of Berlin / 3University Hospital / University Tübingen / University Halle/Saale / University Halle /Saale / University Schleswig Holstein / Campus Kiel / /

MedicalCondition

HER2- breast cancer / tumor / residual disease / disease / HER2- from breast cancer / surgical tumor / breast cancer / /

MedicalTreatment

chemo / endocrine therapy / chemotherapy / surgery / /

Organization

3University Hospital / University of Berlin / /

Person

Sibylle Loibl / /

PublishedMedium

Baseline / /

Technology

gene expression / chemotherapy / /

SocialTag